FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.
Wang Z, Dove P, Wang X, Shamas-Din A, Li Z, Nachman A, Oh YJ, Hurren R, Ruschak A, Climie S, Press B, Griffin C, Undzys E, Aman A, Al-awar R, Kay LE, O'Neill D, Trudel S, Slassi M, Schimmer AD.
Wang Z, et al. Among authors: li z.
Cell Death Dis. 2015 Jul 9;6(7):e1815. doi: 10.1038/cddis.2015.187.
Cell Death Dis. 2015.
PMID: 26158521
Free PMC article.